Literature DB >> 22426510

Targeting imidazoline site on monoamine oxidase B through molecular docking simulations.

Fernanda Pretto Moraes1, Walter Filgueira de Azevedo.   

Abstract

Monoamine oxidase (MAO) is an enzyme of major importance in neurochemistry, because it catalyzes the inactivation pathway for the catecholamine neurotransmitters, noradrenaline, adrenaline and dopamine. In the last decade it was demonstrated that imidazoline derivatives were able to inhibit MAO activity. Furthermore, crystallographic studies identified the imidazoline-binding domain on monoamine oxidase B (MAO-B), which opens the possibility of molecular docking studies focused on this binding site. The goal of the present study is to identify new potential inhibitors for MAO-B. In addition, we are also interested in establishing a fast and reliable computation methodology to pave the way for future molecular docking simulations focused on the imidazoline-binding site of this enzyme. We used the program 'molegro virtual docker' (MVD) in all simulations described here. All results indicate that simplex evolution algorithm is able to succesfully simulate the protein-ligand interactions for MAO-B. In addition, a scoring function implemented in the program MVD presents high correlation coefficient with experimental activity of MAO-B inhibitors. Taken together, our results identified a new family of potential MAO-B inhibitors and mapped important residues for intermolecular interactions between this enzyme and ligands.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22426510     DOI: 10.1007/s00894-012-1390-7

Source DB:  PubMed          Journal:  J Mol Model        ISSN: 0948-5023            Impact factor:   1.810


  54 in total

1.  Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy.

Authors:  Richard A Friesner; Jay L Banks; Robert B Murphy; Thomas A Halgren; Jasna J Klicic; Daniel T Mainz; Matthew P Repasky; Eric H Knoll; Mee Shelley; Jason K Perry; David E Shaw; Perry Francis; Peter S Shenkin
Journal:  J Med Chem       Date:  2004-03-25       Impact factor: 7.446

Review 2.  The therapeutic potential of monoamine oxidase inhibitors.

Authors:  Moussa B H Youdim; Dale Edmondson; Keith F Tipton
Journal:  Nat Rev Neurosci       Date:  2006-04       Impact factor: 34.870

3.  Localization of MAO-A and MAO-B in human brain: a step in understanding the therapeutic action of L-deprenyl.

Authors:  P Riederer; C Konradi; V Schay; E Kienzl; G Birkmayer; W Danielczyk; E Sofic; M B Youdim
Journal:  Adv Neurol       Date:  1987

4.  Potentiation of ligand binding through cooperative effects in monoamine oxidase B.

Authors:  Daniele Bonivento; Erika M Milczek; G Reid McDonald; Claudia Binda; Andrew Holt; Dale E Edmondson; Andrea Mattevi
Journal:  J Biol Chem       Date:  2010-09-20       Impact factor: 5.157

5.  Chromone, a privileged scaffold for the development of monoamine oxidase inhibitors.

Authors:  Alexandra Gaspar; Tiago Silva; Matilde Yáñez; Dolores Vina; Franscisco Orallo; Francesco Ortuso; Eugenio Uriarte; Stefano Alcaro; Fernanda Borges
Journal:  J Med Chem       Date:  2011-07-01       Impact factor: 7.446

6.  Inhibition of monoamine oxidase by C5-substituted phthalimide analogues.

Authors:  Clarina I Manley-King; Jacobus J Bergh; Jacobus P Petzer
Journal:  Bioorg Med Chem       Date:  2011-06-29       Impact factor: 3.641

Review 7.  Monoamine oxidase inhibitors as neuroprotective agents in age-dependent neurodegenerative disorders.

Authors:  Makoto Naoi; Wakako Maruyama
Journal:  Curr Pharm Des       Date:  2010       Impact factor: 3.116

8.  Interactions of imidazoline ligands with the active site of purified monoamine oxidase A.

Authors:  Tadeusz Z E Jones; Laura Giurato; Salvatore Guccione; Rona R Ramsay
Journal:  FEBS J       Date:  2007-03       Impact factor: 5.542

Review 9.  Monoamine oxidase: from genes to behavior.

Authors:  J C Shih; K Chen; M J Ridd
Journal:  Annu Rev Neurosci       Date:  1999       Impact factor: 12.449

Review 10.  MAO inhibitors in mental disease: their current status.

Authors:  J H Dowson
Journal:  J Neural Transm Suppl       Date:  1987
View more
  1 in total

1.  Performance of Force-Field- and Machine Learning-Based Scoring Functions in Ranking MAO-B Protein-Inhibitor Complexes in Relevance to Developing Parkinson's Therapeutics.

Authors:  Natarajan Arul Murugan; Charuvaka Muvva; Chitra Jeyarajpandian; Jeyaraman Jeyakanthan; Venkatesan Subramanian
Journal:  Int J Mol Sci       Date:  2020-10-16       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.